Objective. Opioids are one of the most commonly prescribed medicines for chronic pain. However, their use for chronic pain has been controversial. The objective of this literature review was to identify the role of genetic polymorphisms on patient treatment parameters (opioid dose requirements, response, and adverse effects) for opioids used in malignant and nonmalignant chronic pain. The opioids that this review focuses on are codeine, morphine, oxycodone, tramadol, and fentanyl.
Introduction
It is estimated that the worldwide prevalence of chronic pain is around 34% [1, 2] . Unlike other medical conditions, chronic pain is often difficult to treat effectively, which can negatively impact patients' quality of life. Pain is defined by the International Association for the Study of Pain as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage" [3] . The Australian Medicines Handbook defines chronic pain as pain lasting longer than 12 weeks (three months), and it is usually classified into malignant or nonmalignant pain [4] . Chronic pain can be triggered by the presence of an initial injury or illness or have unknown aetiology [5] . Current treatment options for chronic pain include opioids (e.g., morphine, oxycodone), nonsteroidal anti-inflammatory drugs (NSAIDs; e.g., diclofenac, ibuprofen), COX-2 selective NSAIDS (e.g., celecoxib), paracetamol, and for neuropathic pain tricyclic antidepressants (e.g., amitriptyline), selective neurotransmitter uptake inhibitors (e.g., venlafaxine, duloxetine), and anti-epileptics (e.g., pregabalin, gabapentin, and carbamazepine) [4] .
Mirroring international reports of dramatic increases in opioid dispensing, Australian data [6] have also shown a 15-fold increase between 1992 and 2012, with concomitant increases in both cost (32 fold from $825,000 to $271 million) and adverse events/harms resulting in hospitalizations and even death. It was estimated that during the nine-year study period (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) ) the rate of accidental poisoning deaths from pharmaceutical opioids and other illicit substances increased from 0.78 to 1.19 deaths/100,000 population [6] . There is currently limited evidence on the long-term benefit of opioids in chronic nonmalignant pain [7] [8] [9] . However, there is good evidence for the role of opioids in the management of malignant pain [10] .
Pharmacogenomics is the study of the interaction between genetic factors and the therapeutic efficacy or toxicity of pharmacological products. Genetic polymorphisms in metabolic enzymes, opioid target receptors, and opioid sensitive transporters can play a role in patient response to opioids. With the advancement in knowledge of genetics and pharmacogenomics in particular, there is much evidence now available to show that the genetic make-up of individuals can influence the way they will respond to medicines, be it in terms of response or in experiencing adverse reactions [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .
The aim of this review was to explore how genetic variations can contribute to the variability seen in treatment parameters for opioids such as dosing requirements, response, and opioid-related adverse effects for opioids in the treatment of chronic malignant and nonmalignant pain in adult patients (>18 years of age). Based on opioid prescribing patterns within Australia during 2009 to 2014, the five most commonly utilized opioids-codeine (in combination with paracetamol), tramadol, oxycodone, morphine, and fentanyl-were considered [26] . Figure 1 summarizes the evidence for variants in genes that have been associated with metabolism and treatment outcomes of these opioids.
Methods
The literature search was conducted in two databases, Medline and Embase, using MeSH and free-text terms. The Boolean operator "OR" was used to group search terms into three main subjects. The first subject included terms relating to chronic pain conditions: "chronic pain" or "nonmalignant" or "noncancer" or "neuropathic" or "neurogenic" or "neuralgia" or "cancer pain" or "malignant" or "MeSH exp. Neuralgia" or "MeSH chronic Pain" or "MeSH low back pain" or "MeSH musculoskeletal pain"; second, terms relating to pharmacogenetics: "pharmacogen*" or "genetic*" or "genomic*" or "genotype" or "cytochrome P450 3A4" or "cytochrome P450 2D6" or "CYP3A4" or "CYP2D6" or "OPRM1" or "mu opioid receptor" or "MDR1" or "ABCB1" or "ATP-binding cassette" or "uridine diphosphoglucuronosyltransferase" or "UGT" or "UDP glycosyl transferase" or "COMT" or "catechol o amine methyltransferase" or "val158met" or "MeSH pharmacogenetics"; and last, terms relating to the predefined opioids: "opioid*" or "opiate*" or "fentanyl" or "tramadol" or "codeine" or "morphine" or "oxycodone." Each of the groups of search terms was searched simultaneously with the "AND" Boolean operator to identify original research articles published up to April 2016 on pharmacogenomics of opioids used in the treatment of chronic malignant and nonmalignant pain. The search was limited to articles published in the English language with human subjects.
Using these criteria, 375 papers from Medline and 1,370 papers from Embase were identified, equating to 1,408 individual articles. The title and abstract of each article was reviewed by researcher RAL and verified by VS and EH. Articles that did not answer the research question were excluded. Articles were excluded if they contained: genotypes associated with pain sensation, perception, or opioid addiction, abuse, or withdrawal; pharmacogenomic studies of any medication other than the opioids: fentanyl, morphine, oxycodone, codeine, or tramadol; participants with acute, experimentally induced, and postoperative pain, or if subjects were not genotyped. All abstracts without full text, posters, study protocols, review articles, or any other article about pain, opioids, malignancy, other disease states, or pharmacogenomics in general were also excluded.
Only 32 original articles were identified to meet the criteria and included in this review. As none of the included articles were on the pharmacogenomics of codeine used for chronic malignant or the specific nonmalignant pain conditions searched-low back pain, musculoskeletal pain, neuralgic pain, neuropathic pain, and chronic pain-this review is focused on the opioids: tramadol, oxycodone, morphine, and fentanyl.
Reference lists of past reviews were checked for other papers of interest to ensure that the search was all inclusive. The parameters of the included studies were the analgesic effect, assessed as opioid consumption and its effects, such as the administered dose, frequency of administration, duration of the treatment period, changes in pain scores, and adverse effects. The major parameters were opioid consumption, changes in pain scores, and prevalence of adverse effects.
The findings of this review are categorized by pain subtype (nonmalignant types and malignant pain) and are further subdivided by the specific opioid (or opioids as a class if multiple were analyzed) and the specific polymorphism. Tables 1, 2 , and 3 summarize the significant polymorphisms associated with opioid consumption (mg/day), qualitative measures of response, and adverse effects to opioids, respectively. Both Tables 2 and 3 are separated into two subtables, reflecting the two different study designs: responders vs nonresponders and single cohort populations.
Results

Polymorphisms Affecting Chronic Nonmalignant Pain
Opioids (as a Class) KCNJ6 Polymorphisms. A trend between the rs2070995 AA genotype in KCNJ6, which encodes the potassium inwardly rectifying channels (Kir3.2, GIRK2) essential for opioid receptor transmission, on opioid dosing requirements was shown in 352 Japanese chronic pain patients. The causes of chronic pain that were studied included: malignant, mechanical low back, musculoskeletal, neuropathic, and chronic postsurgery pain. The various opioids and doses taken by the patients were converted into oral morphine equivalent (OME) doses. Homozygous carriers of the KCNJ6 rs2070995 A allele showed a slight increase in opioid dosing requirements (2.03 6 0.45 log mg OME/day) as compared with nonhomozygotes (1.81 6 0.52 log mg OME/day; P ¼ 0.093) to achieve similar pain scores in the 11-point rating scale [27] .
OPRM1 Polymorphisms. A prospective observational study of patients from the United States (>95% CYP2D6 is highly polymorphic in the general population and the various polymorphisms and their correlation to steady-state drug concentrations, therapeutic efficacy and toxicity has been explored for various opioids [47] . CYP2D6 metabolic activity has been classified into 4 phenotypes; ultra-rapid metaboliser (UM), extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM). Theoretically PMs have higher steady state concentrations of the parent drug followed by IMs and EMs, with UMs having the lowest steady state concentration of parent drug (PM>IM and EM>UM). However, to date, the results of such phenotype and steady state concentration co-relation studies have not always been statistically significant [47] .
CYP3A4 polymorphisms occur very rarely in the population and the corresponding phenotypes have been shown to be clinically insignificant in terms of in vivo metabolism. However, it can be inferred that inhibition or induction of CYP3A4 may impact on the level of analgesia experienced after the administration of opioids metabolised by CYP3A4, which may also be dependent on whether the metabolite produced is active or inactive [48] [49] [50] .
UGT2B7 is a phase 2 metabolic enzyme involved in morphine metabolism and is the only enzyme that has been implicated to form both morphine-3-glucoronide and morphine-6-glucuronide via glucuronidation of the 3-and 6-hydroxyl moieties [42, 51] . Hence it is reasonable to infer that alterations in UGT2B7 activity could be responsible for the interpatient variability between the concentrations of morphine and its metabolites, M3G and M6G. UGT2B7 is also involved in glucuronidation of oxymorphone, one of the metabolites of oxycodone [51] .
The mu opioid receptor gene OPRM1, encodes for one of the receptors for opioids, and has been the focus of a number of pharmacogenomics studies due to its known structural and genetic variation and role in analgesic response. The polymorphism that has been the most studied is OPRM1 118(A>G), occurring in 10-15% of the Caucasian population [52] , which causes a change in amino acid at position 40 and alters the activity of the receptor. This polymorphism has been associated with both the efficacy of opioids in the treatment of pain and their implication in dependence [53] .
Polymorphisms in catechol-amino transferase (COMT) have also been implicated in opioid response and pain perception. The most studied COMT polymorphism is 472(G>A) also known as (Val158Met), which reduces enzyme activity, with the homozygous A genotype having the lowest activity [17, 38] .
ATP-binding cassette subfamily B number 1 (ABCB1) also known as multi-drug resistant protein 1 (MDR1) encodes P-glycoprotein (P-gP). P-gP is an efflux transporter that protects tissues such as the brain, intestines and kidneys from the passage of drugs including opioids. Hence polymorphisms which alter the activity of P-gP, and influence central nervous system (CNS) exposure to substrates that have target receptors in the CNS, such as opioids, are inferred to alter their therapeutic efficacy and toxicity [54] . 
Pharmacogenomics and Treatment Parameters to Opioids
Caucasian) analyzed the effect of OPRM1 A118G on opioid analgesia requirements in chronic nonmalignant pain (N ¼ 121) and acute postoperative pain (N ¼ 101). There was no significant difference in OME dose in chronic pain carriers of the 118*G allele vs wild-type however, in patients consuming OME doses above the 75th percentile, the 118*A homozygotes had significantly higher opioid dosing requirements (750 6 544 mg OME/day) than 118*G allele carriers (412 6 41 mg OME/ day; P < 0.005) ( Table 1 ) [28] .
Post Herpetic Neuralgia
Tramadol CYP2D6 Polymorphisms. Multiple prospective studies [13, 25, 29, 30] have been conducted by the same research group studying the influence of CYP2D6 genotypes on tramadol used in postherpetic neuralgia (PHN), defined as ongoing pain for greater than three months after the resolution of the herpes zoster rash. The first study looked at the association between the CYP2D6*4 polymorphism (poor metabolizer [PM] ) and both pain response and adverse drug reactions to tramadol. The CYP2D6*4 polymorphism was significantly associated with lower scores in some of the parameters in the Neuropathic Pain Symptom Inventory (NPSI; burning, squeezing, tingling, and pins and needles; P < 0.05) and improved quality of life scores in the following domains: sociological (P ¼ 0.005), psychological (P ¼ 0.012), and environmental (P ¼ 0.023) (Table 2A) . This study also reported that homozygotes for the CYP2D6*4 polymorphism (PM) were not associated with any tramadol-induced adverse effects [13] . However, a follow-up study concluded otherwise, namely that the CYP2D6*4 polymorphism is associated with the following tramadol-related adverse effects: somnolence (P ¼ 0.009), dizziness (P ¼ 0.007), local site reactions (P ¼ 0.015), headache (P ¼ 0. 039), and nausea and vomiting (P ¼ 0. 017) (Table 3A ) [25] .
Two studies reported no correlation between CYP2D6*10 and pain scores at rest and with movement, or with any of the adverse effects: somnolence, dizziness, local site reactions, headache, hypotension, and nausea and vomiting (all P values > 0.1). Hence there is unlikely to be an association between CYP2D6*10 and treatment outcomes in PHN patients receiving tramadol [25, 30] .
The most recent study by this group analyzed CYP2D6*2 and confirmed a significant association with the pain subtypes of both allodynia (P ¼ 0.029) and pins and needles (P ¼ 0.03) when analyzed with time to pain relief, metabolizer status, and response status (tramadol responder vs nonresponder). However, all pain subtypes did have an association with time, with mean pain scores improving over time [29] . In addition, the CYP2D6*2 polymorphism was also previously shown to be associated with adverse effects: dizziness (P ¼ 0. 029) and headache (P ¼ 0.004) (Table 3A ) [25] .
Low Back Pain
Morphine COMT Polymorphisms. One study evaluated the previously reported association between the COMT (Val158Met) genotype and morphine-induced analgesia in patients with chronic lower back pain. The results showed that both increased age (P ¼ 0.002) and the COMT Met allele (P ¼ 0.048) could predict a lower risk of poor analgesia (poor responders < 40% pain reduction) from intrathecal morphine. Hence, it was concluded that carriers of the Met allele are more responsive to morphine analgesia [17] .
Chronic Postoperative (Caesarean Section) Pain Morphine ABCB1 Polymorphisms. A prospective study was conducted in a Chinese female population to determine the effect of three ABCB1 polymorphisms-C1236T, G2677T/A, and C3435T-on morphine-induced analgesia and the likelihood of developing postcaesarean chronic pain. The prevalence of persistent abdominal wound scar pain was ascertained six months postcaesarean via a survey. The results demonstrated a trend between carriers of the T allele (C3435T) and pain persisting for three months postsurgery (P ¼ 0.07). Kaplan-Meier analyses showed that females homozygous for the 3435*T allele had the longest mean survival time of wound pain in comparison with C allele carriers (CT: P ¼ 0.004; CC: P ¼ 0.014), indicating an association between the 3435*T allele and the progression of chronic postcaesarean pain. The study failed to show any significant differences in the duration of persistent pain between the other genotypes analyzed: C1236T and G2677A/T [19] .
Polymorphisms Affecting Chronic Malignant Pain
Opioids (as a Class)
Genome-Wide Single-Nucleotide Polymorphisms. The European Pharmacogenetic Opioid study (EPOS) aimed to determine the influence of genetic variability on opioid treatment for chronic pain in 2,294 European cancer patients. Patients recruited were on a step III opioid, most commonly morphine, oxycodone, and fentanyl for moderate to severe pain. Each participant was randomized into the development or validation sample and genotyped for 112 SNPs in 25 candidate genes that were inferred to influence opioid response. The significant associations identified were that of the ARRB2 SNPs analyzed;rs3786047, rs1045280, rs2271167, and rs2036657 were related to opioid dose in 880 patients on long-term opioid treatment (>3 months; P ¼ 0.006, *The P values correspond to the statistical difference between the mean morphine equivalent dose (mg/24 hours), which was determined in carriers of the specific genotypes, unless specified in the P values column. ¼ opioid receptor mu 1.
*The P values equates to the significance of the statistically association between carriage of the specific polymorphism and the qualitative measure of response.
0.019, 0.021, and 0.016, respectively). Furthermore, genetic variations in stat6 were associated with opioid dose in patients using fentanyl (rs3024971: P ¼ 0.007; rs167769: P ¼ 0.010) and patients using oxycodone (rs841718: P ¼ 0.008). However, none of the genotyped SNPs had a significant association with opioid dose in both the development and validation sample analyses. Hence, the authors concluded that pharmacogenomics analysis of these SNPs has no role in guiding opioid therapy in European cancer pain patients [31] .
Fladvad et al. in 2012 revisited the EPOS study [31] data to determine if utilization of the opioid dose parameter, which is related to opioid efficacy, influenced the result of this genetic association study. Another six alternative measures were identified and analyzed (average pain intensity, pain "right now", worst pain intensity, pain at its least, pain relief, or pain interference of health-related quality of life), and after correcting for nongenetic factors, there was no significant correlation between the 112 SNPs analyzed and any of these painrelated outcomes. The authors then concluded that there is a lack of association between genetic polymorphisms and opioid response across multiple measures of pain [32] .
A genome-wide association study was conducted in a subset of 1,008 cancer patients from the EPOS study [31] . This study classified poor responders having less than 40% pain relief (N ¼ 145) and good responders having greater than 90% pain relief (N ¼ 293). One million SNPs were significantly associated with the pain relief phenotype at a statistical threshold of P < 0.0001. From this initial screen, 486 candidate SNPs were identified and 72 SNPs were selected, and their association with the pain relief phenotype was explored.
Overall, rs12948783, which maps onto chromosome 17 upstream of RHBDF2 of unknown function, was found to have the greatest association with the pain relief phenotype (P ¼ 8.1 x 10 À 9 ). Carriers of the rs12948783*A allele experienced reduced pain relief from opioids, whereas the common wild-type GG genotype was statistically significantly associated with greater than 90% pain relief. Seven other SNPs were also found to have statistically significant associations.
A significant correlation was determined between pain relief and country of origin, but not with ethnicity. However, the study was unable to probe this finding further as it was underpowered, with 97.6% of the patients being of Caucasian descent [15] .
Follow-up research reviewed the association between the patients' country of origin and pain relief in the EPOS study [31] to determine if population stratification was a confounding factors and whether subethnic genetic differences were responsible for the statistically significant correlation with pain relief as shown in the previous study [15] . A 117-SNP panel was used to generate a statistically significant segregation of four main European subgroups by ethnicity, and not by either country of origin or pain relief phenotype. The authors observed no significant association between genetic clustering with either the country of origin or pain relief phenotype. Hence, the authors concluded that country of origin is not a reliable predictor of ancestral origin and that opioid response in cancer pain is not linked to ancestral origin and may be due to other environmental factors [33] . Laugsand et al. (2011) investigated the results from the EPOS study [21] to determine factors that contributed to the 1,579 patients developing nausea and vomiting in response to opioids, including demographic, diseaserelated, and genetic factors. A total of 96 SNPs in 16 candidate genes involved in opioid and nausea and vomiting pathways were analyzed for their association with nausea and vomiting. The authors concluded that many factors influenced the interindividual differences in nausea and vomiting intensity among cancer pain patients including age, body mass index, use of antiemetics, gender, eight SNPs, type of cancer, type of opioid, and Karnofsky Performance Status (P < 0.01). The SNPs that were identified as having an association were found in the following genes: HTR3B (rs1176744, rs3782025, and rs1672717), COMT (rs165722, rs4680, and rs4633), and CHRM3 (rs10802789 and rs685550) (Table 3B) . Overall, a combination of clinical patient factors along with SNPs in HTR3B, COMT, and CHRM3 may influence the risk of developing nausea and vomiting in cancer patients receiving opioids [21] . OPRM1 Polymorphisms. Two observational studies have analyzed the effect of OPRM1 A118G on general opioid analgesic requirements in patients with chronic malignant and nonmalignant pain. One multicenter study analyzed 352 patients with numerous chronic pain conditions and concluded that a tendency for higher pain scores in a variant dose-dependent manner in carriers of OPRM1 118A>G. However, it did not achieve significance in the subsequent analysis of variance (P ¼ 0.19) [34] . Another study in 112 Chinese chronic cancer pain patients established that the 24-hour opioid dosing requirements were significantly higher in homozygotes of the OPRM1 118*G allele as opposed to carriers of the 118*A allele (GG: 152. 34 ABCB1 Polymorphisms. Two observational studies have looked at the association of ABCB1 3435*T polymorphism and OME dosing requirements. The first, by Lotsch et al. in 2009, identified an OME dose range of 4 to 1,750 mg (133.4 6 203.2 mg/day) in patients with various origins of chronic pain. The required OME dose was significantly lower in patients who were taking P-gP activity-dependent opioids (morphine, fentanyl, oxycodone, and levomethadone) and homozygous for the 3435*T allele (135.4 6 94.5 mg/day), compared with wild-type (274.5 6 265.5 mg/day) (P ¼ 0.014). However, pain scores or adverse effects did not differ between *The P values shows the statistical difference between responders (achieved a defined degree of pain relief) and nonresponders with respect to carriage of the specific polymorphism and the adverse effect(s).
Table 3B
Polymorphisms significantly associated with opioid-related adverse effects in chronic malignant and nonmalignant pain COMT/MCR1/CYP2D6 Polymorphisms. Lotsch et al.
(2009) also analyzed COMT, melanocortin-1 receptor (MCIR), and CYP2D6 variants, which had previously been acknowledged to modulate opioid outcomes, in a cohort of Caucasian patients with variable origins of chronic pain. However, no significant associations were found between polymorphisms in these genes and opioid dose, pain scores, or side effects [34] .
Fentanyl
CYP3A4/5 Polymorphisms
Two studies have analyzed the role of CYP3A5*3 on treatment outcomes with fentanyl in chronic cancer pain patients. In a group of Japanese patients switched from oral opioids to transdermal fentanyl, the absorption rate of fentanyl was found to be significantly higher in homozygous *3/*3 carriers as opposed to heterozygotes (*1/ *3) or wild-type (*1/*1; P ¼ 0.048 and 0.021, respectively). In terms of toxicity, there was a greater incidence of central adverse effects in *3 homozygotes than in *1 carriers (odds ratio [OR] ¼ 3.49, P ¼ 0.029) (Table 3B) , implying a correlation with the higher absorption rate. These results suggest that CYP3A5 polymorphisms may be used in cancer patients to predict transdermal fentanyl response and toxicity [20] . Barratt et al. (2014) analyzed both the CYP3A5*3 and CYP3A4*22 genetic variants in 620 cancer pain patients from the EPOS study [31] on transdermal fentanyl (12.5-700 mg/h) to define any differences in serum fentanyl and norfentanyl concentration and the metabolic concentration ratio (MR). Linear regression models determined the impact of the genetic and other patient factors on the fentanyl and norfentanyl concentration. The results demonstrated a high variation in the delivery rate-adjusted serum fentanyl concentrations and MRs, with overall 43% of the serum fentanyl concentration variability being attributed to delivery rate. Both the CYP3A5*3 and CYP3A4*22 polymorphisms influenced the norfentanyl:fentanyl MR and serum norfentanyl concentrations, but their effect on variability was less than 2% [36] .
ABCB1 Polymorphisms
Takashina et al. (2012) looked at the influence of the ABCB1 C1236T, C3435T, and G2677A/T polymorphisms on the response and toxicity to transdermal fentanyl in Japanese chronic malignant pain patients. (Table 2B) , indicating a greater analgesic response to fentanyl. No other significant associations were identified between any of the genotypes and response to fentanyl or fentanylinduced adverse effects [20] .
Neuro-Immune Activation Pathway Polymorphisms
Barratt et al. (2015) explored whether genetic variability in immune activation and inflammatory signaling pathways, which lead to neuronal adaptation, could alter transdermal fentanyl concentration-response relationships for pain control, cognitive dysfunction, sickness response (reporting two or more of the following symptoms: nausea, tiredness, or depression) and adverse effects in a subset of cancer pain patients from the EPOS study [23] . Serum fentanyl concentrations were not associated with any of the aforementioned outcomes. Each participant was genotyped for a total of 31 SNPs (20 additional SNPs þ EPOS SNPs) across 19 genes. The MYD88 rs6853 variant was associated with a reduced risk of cognitive dysfunction with a relative risk of 0.45 (95% CI ¼ 0.27-0.76, P ¼ 0.003) (Table 3B) . MYD88 is an adaptor protein for some toll-like receptors including TLR4, TLR2, and the interleukin 1 receptor and has a role in inducing innate immune reactions, which can be triggered by opioids. This study also confirmed previous literature that the stat6 rs167769 variant, a cytokine-and growth factor-responsive transcription activator, is able to predict the required fentanyl dose [31] , but that dose alone cannot determine the interpatient variability in pain intensity [23] .
Morphine
OPRM1 Polymorphisms
Numerous studies have explored the association between OPRM1 polymorphisms and response to morphine and its active metabolite, morphine-6-glucuronide (M6G), in chronic cancer pain patients. One of the earlier studies analyzed OPRM1 G172T, A118G, IVS2 þ 31(G>A), and IVS2 þ 691(G>C) polymorphisms in a Caucasian population and concluded that there were no significant differences between the G172T, IVS2 þ 31 (G>A), and IVS2 þ 691(G>C) polymorphisms and required morphine dose, serum concentration of morphine, or its metabolites [28] . This was supported by a later study [29] , which also found no relationship between G172T, IVS2 þ 31(G>A), and other OPRM1 genotypes with serum concentrations of morphine or its glucuronide metabolites, concluding that genotype or allelic frequencies of OPRM1 polymorphisms are similar in morphine responders and nonresponders [29] . Interestingly, in the earlier study [28] the authors showed that homozygous 118*G allele carriers (N ¼ 4, all male) required higher doses of morphine to achieve adequate pain control as compared with carriers of the A allele. The 24-hour morphine dose requirements in males according to genotype were 96 6 92 mg (AA), 78 6 54 mg (AG), and 225 6 143 mg (GG; P ¼ 0.02) ( Table 1) , and the higher doses equated to higher serum morphine concentrations. The authors were unable to explain this difference by examining other factors such as duration of morphine treatment, time since diagnosis, and adverse symptoms [37] .
The OPRM1 A80G polymorphism was analyzed in 45 cancer pain patients of Italian descent taking oral morphine. Pain relief was found to be significantly associated with the A80G polymorphism (P ¼ 0.0001).
Homozygotes for the wild-type A allele experienced greater pain relief as compared with the homozygous G genotype (P 0.001) (Table 2B) , with no significant difference in the heterozygotes. Overall OPRM1 A80G is an independent and strong predictor of analgesic response to morphine [18] .
Two studies have looked at the OPRM1 A118G polymorphism in Japanese cancer pain patients taking oral morphine. One study reported that OPRM1 A118G was not associated with any morphine-related adverse effects [24] , and the other concluded that there was no correlation between the OPRM1 A118G polymorphism and response to morphine [38] .
ABCB1 (MDR1) Polymorphisms
Three studies have analyzed the effect of the ABCB1 (MDR1) polymorphisms: C3435T, C1236T, and G2677T/A on morphine response and adverse effects in cancer pain patients. Campa et al. (2008) , as previously described (section: OPRM1 polymorphisms), determined that pain relief was also significantly associated with the ABCB1 C3435T polymorphism (P ¼ 0.0001). Study participants who were homozygous 3435*T had significantly greater pain relief (P 0.001) as compared with the wild-type CC genotype, with no significant difference identified in the heterozygotes (Table 2B ). This genotype, 3435*TT, was an independent and strong predictor of analgesic response to morphine [18] .
A study on 228 cancer patients taking morphine found an association between ABCB1 G2677T/A and CNS adverse effects of hallucinations, or moderate to severe drowsiness and confusion. Carriers of the common G allele had a lower risk of experiencing the aforementioned CNS side effects as compared with carriers of the T or A alleles, which results in an amino acid change and a greater risk of CNS adverse effects (P ¼ 0.0003). Carriers of the ABCB1 1236*C allele also had a significantly lower level of the CNS side effects (P ¼ 0.004) (Table 3A ) [22] .
Another study in Japanese cancer patients taking oral controlled-release morphine established a lower frequency of fatigue in ABCB1 1236*T homozygotes (P ¼ 0.012) and TT/TT diplotypes at G2677T/A and C3435T (P ¼ 0.011). It was proposed that this effect was due to higher morphine oral clearance in patients carrying this diplotype. Furthermore, it was shown that this diplotype was protective against morphine-induced vomiting as compared with carriers of one G allele at 2677 and one C allele at 3435 (P ¼ 0.011) (Table 3B ) [24] .
Campa et al. 2008 used a composite of OPRM1 A80G and ABCB1 C3435T genotypes to classify the response to morphine analgesia defined as strong, normal, and nonresponders, with a high degree of sensitivity (close to 100%) and specificity (>70%) (refer to Table 4 ). Overall, carriers of the OPRM1 80*G allele had the lowest response to morphine, irrespective of their ABCB1 genotype. This finding has highlighted a way to use pharmacogenomics in the clinical setting [18] .
COMT Polymorphisms
The COMT Val158Met (G472A) polymorphism has been shown to result in a three-to four-fold variation in enzymatic activity depending on the amino acid at this locus (Met allele has lower activity) [39] . Several studies have examined the association between this variant on morphine dosing requirements, response, and adverse effects in cancer pain patients [22, [38] [39] [40] .
In terms of morphine response, one study analyzed the polymorphism in a cohort of Norwegian cancer pain patients and concluded that carriers of the homozygous Val genotype had higher morphine 24-hour dose requirements than the Met allele carriers (P ¼ 0.0025). The difference in dosing requirements could not be explained by other factors, including time since diagnosis, adverse symptoms, perceived pain intensity, duration of morphine treatment, and performance status [39] . This was supported by a follow-up study on Caucasian patients, by the same researchers, which established that the median 24-hour morphine dosing requirements were 90 mg, 80 mg, and 60 mg for the Val/Val, Val/Met, and Met/Met genotype groups, respectively (P ¼ 0.022) ( Table 1) [40] .
A more recent study in a 41 Japanese cancer pain cohort determined that the homozygous A (Met) COMT genotype correlated with both a statistically significant lower plasma concentration of morphine (P ¼ 0.008) and requirements for a lower morphine dose (P ¼ 0.03) as compared with (Val/Met) þ (Val/Val) [38] . It was reported that plasma concentrations on day 1 of dosing were 8.7 6 4.0 ng/mL (Met/Met), 11.9 6 6.2 ng/mL (Val/Met), and 34.1 6 35.7 ng/mL (Val/Val), respectively, and the corresponding morphine daily doses on day 1 were 30 6 0 mg, 28.9 6 3.2 mg, and 43.7 6 21.4 mg, respectively (Table 1) . However, the relationships between genotype and morphine daily dose and plasma concentration were not significant by day 8 [38] .
Rakvag et al. (2008) analyzed a total of 11 SNPs in
COMT in relation to cancer pain patient response to oral morphine. The authors reported that carriers of the most frequently occurring haplotype type 1 (34.5%) (refer to Table 5 ) [40] required lower total morphine doses than patients who did not carry this haplotype (reduction factor 0.71, P ¼ 0.005). This equated to a median 24-hour morphine dose requirement of 60 mg in carriers as compared with 100 mg in noncarriers (P ¼ 0.006) ( Table 1) . Furthermore, the synonymous substitution at rs4818 (Leu136Leu) was associated with significantly different 24-hour morphine dose requirements (60 mg, 80 mg, and 120 mg for the genotypes CC, CG, and GG, respectively, P ¼ 0.042) ( Table 1 ) [40] .
In a prospective case-control study, 228 cancer patients taking morphine, of whom 87.2% were Caucasians, were genotyped for numerous SNPs in COMT. The study reported that the G allele at COMT A4873G was significantly associated with a protective effect against drowsiness and confusion or hallucinations (P ¼ 0.003), as compared with carriers of the A allele (Table 3A ) [22] .
UGT Polymorphisms
Numerous studies have reviewed the impact of UGT2B7 polymorphisms on morphine glucuronidation and the ratio of the plasma concentration of morphine to its metabolites [14, 21, [41] [42] [43] [44] [45] . An initial study analyzed the nonsynonymous UGT2B7 H268Y (C2099T) polymorphism in 70 Norwegian cancer pain patients taking slowrelease morphine. Studies in rats had shown that UGT1A1 was involved in morphine metabolism; hence the UGT1A1*28 polymorphism, which reduces UGT1A1 expression, was also investigated. There was large variation in the metabolite-to-morphine concentration ratios among individuals, and no statistically significant differences were observed between the UGT2B7 H268Y genotypes H/H, H/Y, or Y/Y. Furthermore, no significant differences were observed in metabolite-to-morphine concentration ratios when comparing UGT1A1*28 homozygotes with either *28 allele heterozygotes or homozygous wild-type (*1). This highlights the minor clinical significance of the UGT1A1*28 allele in influencing the rate of metabolism of morphine [41] .
Polymorphisms in UGT2B7 in both the coding and regulatory region were further studied in a cohort of 175 Norwegian cancer patients on long-term morphine therapy. The study identified 12 SNPs, one being nonsynonymous (C2099T), although the clinical significance of this is yet to be determined. A further four SNPs were found to cosegregate with C2099T, but there was no evidence that these polymorphisms affected UGT2B7 activity. Overall, no association was found between both UGT2B7 genotype or haplotype and the ratio of serum morphine to morphine glucuronides in cancer patients with normal renal and hepatic function. This study concluded that the variability in morphine and its metabolite concentrations is mainly attributable to other factors [42] .
Additional UGT2B7 polymorphisms were analyzed both in vitro and in vivo in the Norwegian cohort for their influence on metabolic variability. Genetic screening for promoter region UGT2B7 polymorphisms identified eight SNPs, with six having previously been identified [42] and two being novel at positions -79 (G>A) and -66. Polymorphism -79 (G>A) forms haplotype III and is in linkage disequilibrium with UGT2B7*2, and it was found to be associated with a 2.5-to 7-fold reduction in activity in vitro as compared with wild-type in both Caco-2 colon cells and HepG2 hepatoma cells (P ¼ 0.015, P< 0.001, respectively). However, in cancer pain patients receiving long-term oral morphine, there was no difference in the metabolic ratios of M6G/morphine and M3G/morphine between heterozygous A carriers (N ¼ 6) and noncarriers (N ¼ 169; P ¼ 0.96 and 0.53, respectively). Hence, it was concluded that the -79 (G>A) variation in UGT2B7 has a clinically insignificant effect on morphine metabolism in cancer pain patients [43] .
A further study on 162 Caucasian cancer patients established that the genotypes or allelic frequencies of various UGT2B7 polymorphisms (C161T, A2034G, A2098T, C2099T) [29] are not significantly associated with patients who respond to morphine as opposed to nonresponders. The study also concluded that there was no relationship between genotype and the serum concentrations of morphine or its glucuronide metabolites [14] .
A more recent analysis on a larger cohort of 759 Caucasian cancer pain patients from the EPOS study [31] identified two haplotypes (1a and 1d) in UGT1A1/ UGT1A8 that had weak associations with lower morphine glucuronide to morphine ratios after oral administration of morphine (P < 0.1). This was concluded after screening 41 polymorphisms and haplotypes in UGT2B7, UGT1A1, and UGT1A8 and identifying clinical Table 4 Classification of morphine analgesic response in Italian cancer pain patients using a composite of OPRM1 and ABCB1 genotypes [18] Gene Genotype Responder status
factors that influence the variability of the serum concentration of morphine and its glucuronides, with renal function identified as the main contributing factor [44] .
By contrast, polymorphisms in UGT2B7 have been significantly associated with morphine-induced adverse drug events in a group of Japanese cancer patients taking oral controlled-release morphine. The frequency of nausea was significantly associated with the UGT2B7*2, which appears to have a protective effect as higher rates of nausea were experienced by noncarriers (P ¼ 0.023) (Table 3B ) [24] .
Beta-arrestin2/stat6 Polymorphisms
In one study [14] , polymorphisms in beta-arrestin2 and stat6 significantly correlated with patient response to morphine in 162 Caucasian cancer patients. A significant difference was established between the genotype carrier frequencies in responders to morphine vs nonresponders (who were "switched" to oxycodone) for the following SNPs in beta-arrestin 2: G1182A, G5865A, T8622C, and G11143A (P ¼ 0.021, 0.043, 0.013, 0.043, respectively), where "switchers" more frequently carried the common allele (Table 2A) . There was also a marginally significant increase in the carriage of the uncommon stat6 1714*T allele in switchers over responders (P ¼ 0.049). This study also concluded that there was no relationship between genotype and the serum concentration of morphine or its metabolites [14] .
Oxycodone
CYP2D6 Polymorphisms
Two studies [16, 24] have assessed the correlation between CYP2D6 genotype and the serum concentration of oxycodone and its metabolites (oxymorphone, noroxycodone, noroxymorphone), and response and adverse effects in cancer pain patients. One study investigated the CYP2D6*2 and *10 polymorphisms in a Japanese cohort taking extended-release oxycodone and found that there was no significant association between genotype and oxycodone trough (12 hours postdose) plasma concentrations. However, there was a significant correlation between the trough concentration of oxymorphone and a higher (oxymorphone: oxycodone) ratio in CYP2D6 extensive metabolizers (EMs) as compared with intermediate metabolizers (IMs; P ¼ 0.02 and 0.04, respectively). This significant correlation did not affect the opioid escalation index as measured by the percentage change in dose from baseline [40] .
A cross-sectional study of 450 Caucasian patients from the EPOS study [31] measured the CYP2D6 phenotype frequency within the study population and found that most were EMs (N ¼ 413), followed by PMs (N ¼ 27) and ultrarapid metabolizers (UMs; N ¼ 10). PMs had lower oxymorphone and noroxymorphone serum concentrations in comparison with EMs and UMs (P < 0.001) and a lower ratio of oxymorphone to oxycodone (P < 0.000).
These results support that a reduction in CYP2D6 enzyme activity reduces the conversion of oxycodone to its CYP2D6-specific metabolite oxymorphone. Overall, there were no significant differences between each of the phenotypes and the dose required for analgesia, pain scores, or side effects of nausea, tiredness, or negative impacts on cognitive function [45] .
CYP3A5, ABCB1, OPRM1 Polymorphisms
The Naito et al. 2011 study, as previously discussed, also analyzed the effect of genetic polymorphisms in CYP3A5, ABCB1, and OPRM1 on plasma concentrations of oxycodone and its metabolites, adverse effects, and the dose escalation requirements in Japanese cancer patients. The study found that the trough (predose) concentration of the CYP3A5-specific metabolite noroxycodone and the noroxycodone:oxycodone ratio were significantly higher in CYP3A5*1 carriers as opposed to CYP3A5 *3/*3 homozygotes (P ¼ 0.01 and <0.01, respectively). Furthermore, the opioid escalation index was significantly higher in the homozygous *3/*3 group as opposed to *1 carriers (P ¼ 0.02) ( Table 2B ). The trough noroxycodone concentrations in the *3/*3 group were inversely associated with oxycodone dose escalation. The study also identified a lack of association between either the oxycodone and metabolite plasma concentrations or opioid escalation index and the ABCB1 C3435T or OPRM1 A118G genetic polymorphisms. Lastly, no genotype was significantly associated with any adverse effects relating to oxycodone dose escalation [16] .
Discussion
Efforts to elucidate the genetics of treatment outcomes such as response to, and vulnerability to adverse effects of, chronic opioid treatment are of vital importance. The ideal treatment for any condition is the most efficacious medicine that is also the most tolerable in terms of Evidence from recent studies show that several polymorphisms in ABCB1, OPRM1, and COMT (Table 1) have been significantly associated with opioid dosing and could be useful in determining opioid dose for patients. It was encouraging to see several significant associations being replicated even though studies had focused on different opioids. Response to opioid treatment has been studied for most of the opioids, except codeine. However, ABCB1 for morphine is the only gene to have evidence of successful replication for treatment response (Table 2B ) and adverse effects (Tables 3A and 3B) . Interestingly, most studies that showed statistically significant associations focused on patients with chronic pain associated with malignancy, likely reflecting the fewer studies investigating chronic nonmalignant pain. One of the limitations of this study was the use of selective pain-related search terms-low back pain, neuralgia, neuropathic pain, and musculoskeletal pain-which may have led to the exclusion of studies that focused on other chronic nonmalignant pain conditions, such as sickle cell anaemia. This may have contributed to the lack of studies addressing the pharmacogenomics of codeine in chronic pain.
Even though the variants highlighted show promise for implementation in the clinical setting, some results have either been inconsistent or lack further validation. There are several reasons for the lack of replication. A critical limitation of most pharmacogenomic studies to date is a lack of sufficient power to detect true positive associations. It is rather difficult to come to a conclusion in underpowered studies, as one cannot be sure that the negative result is due to the lack of power or the positive result is entirely due to chance. The other notable factor that some studies fail to take into account is correcting for multiple testing. When the number of variants tested increases, the significance level should be decreased proportionately. The P value threshold for significance must be adjusted to control the overall false positive rate.
Important differences in allele frequencies between ethnic groups should also be taken into consideration when designing pharmacogenomics studies. For example, CYP2D6 plays a vital role in the metabolism of many of the opioids, but it is also the gene that shows great interethnic variability. The prevalence of PMs and UMs range from 7-10% and 4.3% in Caucasians and about 0-1% in Asians, respectively [55] . The disparity between allele frequencies in different ethnic groups has also shown that some ethnic groups are either more susceptible to toxicity or response [50] . This difference in allele distribution may explain the lack of reproducible results across different ethnicities.
Furthermore, unlike cancer where the response to treatment can be easily quantified, response to chronic pain is very subjective and much more difficult to define. This makes comparing different studies with different methods complex. These are some of the several factors that need to be taken into account when designing pharmacogenomic studies.
Conclusion
Currently, there are few validated studies to form a strong evidence base to support pharmacogenomics testing when initiating opioid therapy. However, the field of pharmacogenomics in chronic pain is likely to expand over the coming years with the increasing number of treatment options available and larger cohorts being assembled in order to identify true associations.
